Chris Moore’s practice focuses on public and private company merger and acquisition transactions and activist defense.

Chris has significant experience in both cross-border and domestic transactions, as well as carve-outs and LBOs. He also advises companies and their boards of directors on takeover defense and governance matters.

Chris has advised a broad range of public and private clients across many industries, with a focus on the technology and life sciences sectors.

Chris joined the firm as a partner in 2022.

Read More

notable-experiences

Notable Experience

  • T-Mobile in its pending up to $1.35 billion acquisition of Ka’ena and its subsidiaries and brands, Mint Mobile, Ultra Mobile, and Plum.

  • OpenText in its $6 billion acquisition of Micro Focus.

See More

Previous Experience

  • Oracle in its $28 billion acquisition of Cerner Corporation.

  • Zendesk in its announced $4 billion acquisition of Momentive.

  • Walmart in its $16 billion acquisition of a majority stake in Flipkart.

  • Marvell Technology Group in its $10 billion acquisition of Inphi, its $6 billion acquisition of Cavium, and its $450 million acquisition of Aquantia.

  • Wise Road Capital in its announced $1.4 billion acquisition of Magnachip Semiconductor.

  • Dialog Semiconductor in its $500 million acquisition of Adesto Technologies and its acquisition of Silego.

  • Synopsys in its $565 million acquisition of Black Duck Software, its $330 million acquisition of WhiteHat Security, and its acquisitions of Moortec, Tinfoil Security, Qualtera, MorethanIP, Code DX, Protecode, Gold Standard Simulations, Cigital, and Codiscope.

  • Atlassian in its acquisitions of OpsGenie, AgileCraft, Code Barrel, Halp, Mindville, Chartio, ThinkTilt, and Percept.AI.

  • Sabre in its announced $360 million acquisition of Farelogix and its acquisition of Radixx.

  • zulily in its $2.4 billion sale to Liberty Interactive Corporation.

  • Eli Lilly in its $960 million acquisition of CoLucid Pharmaceuticals.

  • XenoPort in its $446.6 million sale to Arbor Pharmaceuticals.

See More

Selected Activities

Corporate Advisory Board, Thomson Reuters Practical Law

Member, Working Group for the ABA 2017 Strategic Buyer/Public Target M&A Deal Points Study

Review Team Member, ABA M&A Carveout Transactions Deal Points Study